Immunocore appoints CMO
This article was originally published in Scrip
Immunocore, a biotechnology company developing drugs to treat cancer, viral infections and autoimmune disease, has named Christina Coughlin chief medical officer. Dr Coughlin will be responsible for providing medical and regulatory leadership to the preclinical and clinical programs for the company. Most recently, Dr Coughlin was leading two early development program at Novartis in checkpoint inhibition and PI3'kinase inhibition. Prior to this she was international project team leader at Morphotek, a monoclonal antibody company acquired by Eisai in 2007.